Chahra Louafi - DBV Technologies Director
| DBVT Stock | USD 0.66 0.02 2.94% |
Director
Ms. Chahra Louafi was Director Representative of CDC Entreprises at DBV Technologies SA since December 16, 2010. She is the Investment Director for CDC Entreprises, Fund Management for InnoBio. Before joining CDC Entreprises in 2001, Ms. Louafi was in charge of initiating and implementing projects, as well as creating in a private business incubator specialized in biotechnology, Mendel Partner. Within CDC Entreprises, she was in charge, inter alia, of funds of funds investments focused on seed funds and biotech funds, and tech transfer transactions. In October 2009, she joined the management team of InnoBio fund, a fund dedicated to biotech companies, managed by CDC Entreprises and invested by the pharmaceutical industry since 2010.
| Tenure | 14 years |
| Address | 177-181 Avenue Pierre Brossolette, Montrouge, France, 92120 |
| Phone | 33 1 55 42 78 78 |
| Web | https://www.dbv-technologies.com |
DBV Technologies Management Efficiency
The company has return on total asset (ROA) of (0.2225) % which means that it has lost $0.2225 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.4347) %, meaning that it created substantial loss on money invested by shareholders. DBV Technologies' management efficiency ratios could be used to measure how well DBV Technologies manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.42 in 2024. Return On Capital Employed is likely to drop to -0.66 in 2024. At this time, DBV Technologies' Liabilities And Stockholders Equity is comparatively stable compared to the past year. Change To Liabilities is likely to gain to about 3.3 M in 2024, whereas Total Current Liabilities is likely to drop slightly above 31 M in 2024.Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Raquel MS | HCW Biologics | N/A | |
| Hoyoung Huh | Rezolute | 47 | |
| Gary Sollis | ESSA Pharma | 60 | |
| Samir Patel | Rezolute | 46 | |
| Tae Kim | Rezolute | 34 | |
| Scott Requadt | ESSA Pharma | 49 | |
| Raymond Andersen | ESSA Pharma | 66 | |
| Yutaka Kobayashi | MediciNova | 54 | |
| David Welch | Rezolute | 56 | |
| Gilbert Labrucherie | Rezolute | 44 | |
| Franklin Berger | ESSA Pharma | 68 | |
| Otello Stampacchia | ESSA Pharma | 48 | |
| Yoshio Ishizaka | MediciNova | 78 | |
| David Parkinson | ESSA Pharma | 67 | |
| Marianne Sadar | ESSA Pharma | 52 | |
| Hideki Nagao | MediciNova | 64 | |
| Young Sung | Rezolute | N/A | |
| YoungJin Kim | Rezolute | N/A | |
Management Performance
| Return On Equity | -0.43 | ||||
| Return On Asset | -0.22 |
DBV Technologies Leadership Team
Elected by the shareholders, the DBV Technologies' board of directors comprises two types of representatives: DBV Technologies inside directors who are chosen from within the company, and outside directors, selected externally and held independent of DBV. The board's role is to monitor DBV Technologies' management team and ensure that shareholders' interests are well served. DBV Technologies' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, DBV Technologies' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Pascale Ehouarn, Industrial Development and Production Director | ||
| Claude Thebault, Medical Director | ||
| Wence Agbotounou, Chief Clinical Trial Officer | ||
| Laurent Martin, Director of Regulatory Affairs | ||
| Caroline Daniere, Chief Staff | ||
| Didier Hoch, Director | ||
| Daniel Tass, CEO Director | ||
| Hugh Sampson, Chief Scientific Officer | ||
| Alan Kerr, Senior Affairs | ||
| Pascal Wotling, Chief Officer | ||
| Charles Ruban, Chief Development Officer | ||
| Nathalie Donne, Director of Bus. Devel. and Corporate Communication | ||
| Lucie Mondoulet, Director of Research Department | ||
| Anne Pollak, Head Relations | ||
| Chahra Louafi, Director - Representative of CDC Entreprises (Innobio) | ||
| Peter Hutt, Independent Director | ||
| Michele Robertson, Chief Officer | ||
| Rafaele Tordjman, Director - Representative of Sofinnova Partners | ||
| Bertrand Dupont, Co-Founder and Sr. Executive VP of Technology | ||
| Joseph Becker, VP Communications | ||
| Sbastien Robitaille, Chief Officer | ||
| Veronique Foutel, Director of Strategic Marketing | ||
| Edward MBA, Senior America | ||
| Rafale Tordjman, Director - Representative of Sofinnova Partners | ||
| George Horner, Director | ||
| Torbjorn Bjerke, Independent Director | ||
| Pharis Mohideen, Chief Officer | ||
| PierreHenri Benhamou, Chairman of the Board, CEO | ||
| Virginie MBA, CFO Officer | ||
| Torbjrn Bjerke, Independent Director | ||
| Mailys Ferrere, Director | ||
| David Schilansky, COO |
DBV Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is DBV Technologies a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.43 | ||||
| Return On Asset | -0.22 | ||||
| Operating Margin | (1.34) % | ||||
| Current Valuation | (70.28 M) | ||||
| Shares Outstanding | 192.34 M | ||||
| Shares Owned By Institutions | 19.64 % | ||||
| Number Of Shares Shorted | 548.44 K | ||||
| Price To Earning | (8.25) X | ||||
| Price To Book | 0.95 X | ||||
| Price To Sales | 8.49 X |
Pair Trading with DBV Technologies
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if DBV Technologies position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in DBV Technologies will appreciate offsetting losses from the drop in the long position's value.Moving together with DBV Stock
| 0.74 | JNJ | Johnson Johnson Financial Report 18th of July 2024 | PairCorr |
Moving against DBV Stock
| 0.75 | NUVB | Nuvation Bio Financial Report 2nd of May 2024 | PairCorr |
| 0.42 | IOVA | Iovance Biotherapeutics Financial Report 14th of May 2024 | PairCorr |
| 0.41 | ZNTL | Zentalis PharmaceuticalsL Financial Report 8th of May 2024 | PairCorr |
The ability to find closely correlated positions to DBV Technologies could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace DBV Technologies when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back DBV Technologies - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling DBV Technologies to buy it.
The correlation of DBV Technologies is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as DBV Technologies moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if DBV Technologies moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for DBV Technologies can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in DBV Technologies. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in real. For more information on how to buy DBV Stock please use our How to Invest in DBV Technologies guide.You can also try the Portfolio Manager module to state of the art Portfolio Manager to monitor and improve performance of your invested capital.
Complementary Tools for DBV Stock analysis
When running DBV Technologies' price analysis, check to measure DBV Technologies' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy DBV Technologies is operating at the current time. Most of DBV Technologies' value examination focuses on studying past and present price action to predict the probability of DBV Technologies' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move DBV Technologies' price. Additionally, you may evaluate how the addition of DBV Technologies to your portfolios can decrease your overall portfolio volatility.
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios |
Is DBV Technologies' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of DBV Technologies. If investors know DBV will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about DBV Technologies listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.38) | Revenue Per Share 0.0825 | Quarterly Revenue Growth 0.144 | Return On Assets (0.22) | Return On Equity (0.43) |
The market value of DBV Technologies is measured differently than its book value, which is the value of DBV that is recorded on the company's balance sheet. Investors also form their own opinion of DBV Technologies' value that differs from its market value or its book value, called intrinsic value, which is DBV Technologies' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because DBV Technologies' market value can be influenced by many factors that don't directly affect DBV Technologies' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between DBV Technologies' value and its price as these two are different measures arrived at by different means. Investors typically determine if DBV Technologies is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, DBV Technologies' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.